What's in the Cards for Amgen (AMGN) This Earnings Season? [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Factors to Consider Amgen's product sales are expected to be the lowest in the first quarter per historical trends due to the impact of benefit plan changes, insurance re-verification and increased co-pay expenses as U.S. patients work through deductibles. First-quarter 2024 total revenues are expected to grow roughly 20% year over year. The Zacks Consensus Estimate for total revenues is $7.38 billion. Amgen's product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia, and Blincyto, among others. However, prices of most products are expected to have declined. The Zacks Consensus Estimate for Prolia, Repatha, Evenity and Blincyto sales are pegged at $1.0 billion, $452.3 million, $334.0 million and $240.0 million, respectively. Our estimates for Prolia, Repatha, Evenity and Blincyto sales are pegged at $997 million, $448.0 million, $330.8 million and $227.1 million, respectively. In addition, higher volumes of newer drugs
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times]The New York Times
- FDA approves Amgen's treatment for most deadly form of lung cancer [CNBC]CNBC
- Amgen Drug Wins US Approval for Advanced Small Cell Lung Cancer [BNN Bloomberg (Canada)]BNN Bloomberg
- AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024PR Newswire
- Bone Metastasis Treatment Market To Reach USD 38.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website